Pharma IQ presents Europe’s dedicated forum for fast, effective & integrated lead discovery

Save up to £200 by booking early (see back page) HIT-HIT-TOTO-LEAD-LEAD

Enhancing lead generation to accelerate quality compounds into lead optimisation

Conference: 18th & 19th July 2005 • Masterclass: 20th July 2005 Detailed case studies will be Café Royal, London, UK presented by:

Discover the hit-to-lead successes and failures experienced by Pfizer leading pharma companies to understand how you can improve Roche decision-making and generate better quality leads faster. Wyeth ➨ Explore proven and creative hit-to-lead strategies and key criteria to increase the speed and efficiency of your processes AstraZeneca ➨ Enhance the quality of validated hits to improve the prioritisation and Bayer Healthcare selection of hit and lead series Merck KGaA ➨ Analyse DMPK data effectively to optimise properties at an early stage and to drive and prioritise hit-to-lead projects University of Sheffield ➨ Optimise -based and structure-based approaches to virtual Sanofi-Aventis screening to aid lead identification and assessment ➨ Apply to enhance all stages of early drug discovery Tripos ➨ Improve the design and quality of hit-to-lead libraries to speed the University of generation and optimisation of lead series Heidelberg ➨ Ensure research efforts are focussed only on the most promising compounds to increase the number of successful candidates in your Novartis development pipeline Inpharmatica

Don’t miss the interactive masterclass on 20th July GPC-Biotech Chemogenomics in Drug Discovery Led by Professor Hugo Kubinyi IMIM Media Partners “Excellent networking opportunities, Johnson & Johnson very interesting presentations.”

Vincent Mikol, Sanofi-Aventis Array Biopharma  

+44 (0)20 7368 9300 +44 (0)20 7368 9301 www.iqpc-pharma.com/2484a UK Freephone: 0800 652 2363 [email protected] to-lead. It will discuss how high quality materials are provided to improve the DAY ONE: 18th July 2005 speed and quality of the process, and in particular will discuss: • Optimising hit finding and generation 08:30 Coffee and registration • Exploring the best approaches and technologies for screening • Providing excellent starting points for hit-to-lead 09:00 Pharma IQ welcome Martin Klumpp, Lab Head, Assay Development & Screening, Novartis

09:10 Opening remarks and presentation from the Chair: 15:00 Enhancing hit quality and diversity from HTS through evolving Search for new leads - from serendipity to design hit selection schemes The is short of new drugs. As only a few lead structures The HTS process at Wyeth is currently undergoing considerable change, and the can be optimised to clinical candidates and many such projects fail in the process by which project teams select from the hits generated by HTS is clinics, there is an urgent need for new leads. This presentation will discuss and evolving to keep pace. The consistent focus has been on enhancing the quality explore the following lead sources and strategies: (in terms of 'lead-likeness') and diversity (in terms of chemical scaffolds, • Plant and microbial natural products fingerprints, etc) of the selected hits. After secondary screening and further • Serendipitous and rational approaches filtering, this approach aims to provide the team with the best possible • Chiral and metabolic switch selection of candidates for the lead optimisation phase of the project. The • various methods of hit selection and filtering that have been employed and the • Virtual screening evolution of the process will be presented, exemplified by results from several • Structure-based, computer-aided and fragment-based design recent and representative projects at Wyeth. Hugo Kubinyi, Professor of Pharmaceutical Chemistry, Iain McFadyen, Senior Research Scientist II, Chemistry and Screening Sciences, University of Heidelberg, and formerly BASF Wyeth

10:00 The hit-to-lead process at Bayer Healthcare 15:45 Coffee In the hit selection process, the understanding of compound liabilities needs to be ensured as early as possible in order to identify leads with the minimum 16:15 Application and benefits of knowledge-driven chemistry number of liabilities. This presentation will explore the key requirements and Tripos Discovery Research employs knowledge-driven informatics processes to features of Bayer’s hit-to-lead process, and will discuss two case studies in computationally assess every compound it makes for biological relevance and Cancer and Thrombosis. The session will consider: synthetic feasibility. These proven technologies have enabled Tripos to reduce its • In silico parameters customers' lead identification and optimisation timelines by up to 30%. Case • In vitro high throughput screening data studies will be presented that support this approach to lead identification and • Physicochemical and ADMET data the development of follow-up compound libraries. Berthold Hinzen, Director of , Dr. Mark Allen, Senior Vice President, Discovery Research and Managing Bayer Healthcare Director, Tripos Discovery Research, Ltd. 10:45 Coffee 17:00 Lead discovery at Roche Palo Alto This presentation will focus on the development approaches that are being 11:15 Hit identification and validation to speed hit-to-lead implemented in Roche to enhance the cross-functional process of lead High throughput screening and other hit generation techniques usually result in discovery. Multiple approaches for novel lead finding and tools to assess the huge numbers of actives being identified. Over the last couple of years, Merck hits identified will be described. Examples of the application of these tools will KGaA has implemented various processes and tools that allow a better also be discussed. characterisation of HTS hits by experimental and calculated data. Tools were Michael Dillon, Director, Medicinal Chemistry, also developed that help display those characteristics in a convenient fashion. Roche Palo Alto This session will discuss: • Improvements that have been implemented in high throughput screening 17:45 Chair’s summary and close of day one • What data is being used for the characterisation of hits • How the data is provided to help prioritisation of hit and lead series Michael Arlt, Department Manager, Global Medicinal Chemistry Lead Finding, Merck KGaA DAY TWO: 19th July 2005

12:00 Optimising DMPK properties in hit-to-lead – an AstraZeneca 08:30 Coffee and registration perspective DMPK properties are being assessed much earlier in drug discovery now to 09:00 Chair’s welcome avoid complications in lead optimisation. In this session, AstraZeneca will Iain McFadyen, Senior Research Scientist II, Chemistry and Screening Sciences, review their approach and show how early DMPK analysis has influenced Wyeth projects downstream. • Optimising compounds using experimental and computational tools 09:15 Optimising ligand-based approaches to virtual screening • Using DMPK data to drive hit-to-lead projects Given an initial hit, similarity searching provides a simple way of prioritising • Safety considerations: reactive metabolites etc compounds in a corporate or public database for biological testing, and thus of Richard Weaver, Team Leader, DMPK Research, Physical and Metabolic Sciences, identifying potential new leads. This session will describe recent work that AstraZeneca provides effective tools for fingerprint-based virtual screening. • Conventional approaches to similarity-based virtual screening 12:45 Enhancing profiling strategies: Compound prioritisation and • Use of nearest neighbour information to increase search effectiveness optimisation • Combination of similarity searches when several hits are available Inpharmatica has developed an interactive and visually engaging interface, Peter Willett, Head, Department of Information Studies, Admensa InteractiveTM, which allows scientists to select compounds with the University of Sheffield best overall balance of properties and potential for success. The interface also includes a predictive ADME modelling suite, the results of which can be 10:00 Identifying and assessing potential leads through structure- incorporated with any in vitro and in vivo measurements (such as potency and based virtual screening selectivity) in a unique prioritisation suite. This presentation will give a brief Structure-based virtual screening has become an important tool in the hit-to- overview of Admensa InteractiveTM and will share a number of case studies lead process. This session will explore how this technique can be applied in demonstrating its applicability in the hit-to-lead stages of drug discovery. order to aid lead generation and assessment. Joelle Gola, Computational Chemist, ADME modelling, • Generating plausible hypotheses for molecular recognition (pose prediction) Inpharmatica • Rank-ordering potential lead series (affinity prediction) • Generating and assessing potential leads (fragment screening) 13:15 Networking lunch Romano Kroemer, Head of , Sanofi-Aventis 14:15 Generating high quality candidates for effective hit-to-lead

This presentation will explore how Novartis uses HTS to effectively support hit- 10:45 Coffee  

+44 (0)20 7368 9300 +44 (0)20 7368 9301 www.iqpc-pharma.com/2484a UK Freephone: 0800 652 2363 [email protected] 11:15 Lead-hopping via structure-based drug design 16:15 2nd generation kinase inhibitors In order to increase the chances of success against a given target, it is a great • kinase inhibitors help to start with leads from multiple chemical classes. One way to achieve • Privileged structures in target gene family approach for protein kinases such diversity is via structure-based "lead-hopping" or "lead-morphing". This • Chemo-centric approaches to kinase inhibitor drug discovery presentation will use several case studies to describe this approach and how it is • The selectivity issue applied using: • Kinase inhibitors in cancer versus other therapeutic indications - the • One or more experimentally-determined ligand:target complex structures paradigm • A docking program which can reproduce the bound structures with good Bert Klebl, Senior Director, Discovery Biology, accuracy GPC-Biotech • A scoring algorithm capable of distinguishing true ligands for decoys • A program which can iteratively modify the starting structures, in order to 17:00 Chair’s summary and close of conference generate novel structures • A library of virtual fragments to use in the computational process • A library of real fragments to use in subsequent structural studies Guy Vigers, Senior Research Investigator, MASTERCLASS: 20th July 2005 09:00 – 12:30 Array BioPharma Inc. Chemogenomics in Drug Discovery 12:00 Data reduction, visualisation & integration to streamline hit-to- lead Chemogenomics is the integration of chemistry and genomics to discover Current drug discovery is blessed with a richness of data undreamt of even 10 drug candidates and to speed up the drug discovery process. For this purpose, years ago. The challenge today is to sift these millions of data points to a chemical libraries are tested in target families, to arrive at active and highly meaningful number, which can then enable quality decision-making on classes selective compounds that are inhibitors of a certain enzyme (e.g. a receptor of compounds. This presentation will demonstrate how data reduction, kinase) or are agonists, antagonists or blockers of a receptor subtype, ion visualisation and integration techniques are applied in J&J to deal with these channel or transporter. Such approaches have already been followed in drug data volume issues. research, but chemogenomics now provides a systematic concept for this Trevor Howe, Research Fellow, Head of Molecular Informatics, strategy. Johnson & Johnson PRD This workshop will demonstrate how chemogenomics can benefit the 12:45 Networking lunch medicinal chemist and will explore: • The use of chemogenomics in all stages of early drug discovery: library design, hit and lead search, and lead optimisation 14:00 Driving drug discovery with chemogenomics • Privileged structures: from target family-directed masterkeys to highly Chemogenomics is an emerging multi-disciplinary research area aiming at selective drugs annotating all molecules to all proteins through the exploitation of their • Changing the selectivity of biologically active compounds (the SOSA respective fundamental phylogenetic classifications. This session will present approach) some of our recent efforts to identify and classify both chemical and biological entities as an essential prerequisite for extracting knowledge from biochemical Participants are encouraged to discuss their own examples and experience as data by means of novel integrative biochemoinformatics tools: well as examples from literature. • Hierarchical classification schemes for molecules and proteins • Construction of annotated chemical libraries About your workshop leader: • Identification of privileged scaffolds Professor Hugo Kubinyi is a medicinal chemist with 35 years of • In silico industrial experience. For 17 years he was responsible for the Jordi Mestres, Head of Chemogenomics, Molecular Modelling, Protein Crystallography and Drug Design IMIM groups at BASF Pharma and Agro, later also for Combinatorial Chemistry. He is Professor of Pharmaceutical Chemistry at the University of Heidelberg, 14:45 Enhancing GPCR focussed drug discovery former Chair of The QSAR and Modelling Society (currently Advisor to the Inpharmatica has developed GPCR SARfari as a unique, comprehensive and Chair) and an IUPAC Fellow. Kubinyi has published about 100 scientific papers easily accessible knowledge base, containing the relevant chemical, natural and is author and editor of six textbooks, including Chemogenomics in Drug ligand and biological information on all 297 human rhodopsin-like (non- Discovery (Wiley-VCH, 2004). olfactory) GPCRs. This integrated and highly curated bioinformatics and database empowers: • Design of compounds and focused libraries for GPCRs and specific GPCR subtypes Who will you meet? • optimisation • Prediction of compound selectivity issues Senior level Directors, Managers and Scientists working in: • Identification of GPCR counter screens (based on binding site and/or ligand Drug Discovery, Medicinal Chemistry, Lead Discovery, Lead Generation, similarities) Discovery Research, Drug Design, Biochemistry, Combinatorial Chemistry, Edith Chan, Head of Molecular Design, Computational Sciences, Cheminformatics, Bioinformatics, Molecular Inpharmatica Modelling, Biomolecular Screening, HTS, Virtual Screening

15:05 Coffee

15:30 Planning for success: Differentiating the hits/leads and Sponsorship & Exhibition Opportunities optimising the design of hit-to-lead libraries Pharma IQ’s Hit-to-Lead conference is a timely event that will create a Key to tackling the critical productivity and attrition problems in the drug unique industry forum to discuss tools that help improve the speed and discovery process is the selection of the best lead and efficient optimisation to quality of lead generation. This focussed and targeted event will be an a drug candidate. Approaches that consider broader safety and selectivity issues excellent platform to initiate new business relationships through tailored early in the process, and increase the proportion of actives synthesised will be networking. discussed For sponsorship and exhibition opportunities please call • Use of biological fingerprints to differentiate leads and identify selectivity +44 (0)20 7368 9500 or email [email protected]. issues early, including chemogenomic analysis of targets • Use of activity models to improve the yield from HTS and to optimise the Session Sponsor design of libraries Jonathan Mason, Executive Director Medicinal Informatics, Structure & Design, Pfizer Global R&D Tel: + 1 314 647 1099 Fax: + 1 314 647 9241 Alexander Alex, Director Computational Chemistry, Email: [email protected]

Pfizer Global R&D Website: www.tripos.com  

+44 (0)20 7368 9300 +44 (0)20 7368 9301 www.iqpc-pharma.com/2484a UK Freephone: 0800 652 2363 [email protected] HIT-TO-LEAD Conference: 18th & 19th July 2005 • Masterclass: 20th July 2005 • Café Royal, London

REGISTRATION FORM 5 WAYS TO REGISTER To speed registration, please provide the priority code located on the mailing label or in the box below.  Freephone: 0800 652 2363 or +44 (0)20 7368 9300 My registration code is S Fax: +44 (0)20 7368 9301 Please contact our database manager on +44(0) 207 368 9300 or at [email protected] quoting the registration code above to inform us of any changes or to remove your details. Post: your booking form to IQPC Ltd. Anchor House, 15-19 Britten Street, London, SW3 3QL

 Online: www.iqpc-pharma.com/2484a  email: [email protected]

www.iqpc-pharma.com/2484a

TEAM DISCOUNTS TEAM DISCOUNTS: IQPC recognises the value of learning in teams. Groups of 3 or more booking at the same time from CONFERENCE PRICES the same company receive a 10% discount. 5 or more receive a 15% discount. 7 receive a 20% discount. Only one EARLY BIRD Standard Prices CEE Countries** discount available per person. PACKAGES DISCOUNT Book and pay by 17th June 2005 STANDARD PRICE VENUE & ACCOMMODATION ■ Silver Package Save £200 Conference + Save £50 £1349 + VAT VENUE: Café Royal (No accommodation) £1398 + VAT Masterclass £1548 + VAT 68 Regent Street London W1B 5EL Tel: +44 (0)20 7437 9090 ■ Conference only £1199 + VAT £1199 + VAT £950 + VAT ACCOMMODATION: Overnight accommodation is not ❑ Masterclass only £399 + VAT included in the registration fee. However, reduced rates Academic discount rates of 50% off the standard price are available at Le Meridien Piccadilly, Tel: +44 (0) 207 **Central and Eastern European Countries: Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Latvia, 851 3100 or book online www.lemeridien.com/GA2 Lithuania, Moldova, Poland, Romania, Russia, Slovakia, Slovenia, Ukraine, Yugoslavia, Serbia and Montenegro, Turkey, Macedonia, Accommodation is also available at the Thistle Marble Georgia, Kazakhstan, Moldova, Uzbekistan Arch Hotel, Tel: +44 (0) 20 7514 2623. Please call the Early bird discounts are not valid in conjunction with any other offer. Payment must be received with bookings to qualify for early bird hotels direct and ALWAYS QUOTE PROMOTIONAL discounts. VAT is charged at 17.5% where applicable. CODE "GA2" when booking. It is advisable to book early Can’t make the event? Purchase all the conference documentation on CD RO: CD Rom + Audio £599 + VAT = £712.82 to secure the reduced rate. Alternatively please search DELEGATE DETAILS www.cityhotelaccommodation.com DELEGATE 1 Please photocopy for each additional delegate Mr ■ Mrs ■ Miss ■ Ms ■ Dr ■ Other ■ Digital Conference on CD ROM First Name Family Name A digital version of the conference proceedings, including all the presentations in audio format Position "An excellent service, an invaluable reference tool, easy to Email access and easy to store - all in all a top product" ■ Yes I would like to receive information about products and services via email Recent digital conferences available - Organisation £599 plus VAT each Nature of business ■ Recent digital conferences available ■ Hit-to-Lead (November 2004) Address ■ Predictive ADME-Tox (April 2005) ■ Compound Management (May 2005) Postcode Country Please send me conference materials indicated above. I have filled out credit card details above Telephone Fax For further information please call: 0207 368 9300 Dept. Head Title or email: [email protected]. To search IQPC’s archived conference documentation, visit: Name of person completing form if different from delegate: www.iqpcknowledgebank.com Your order is risk free! If you are not happy with the content, simply Signature ______return the products to us within seven days for a full refund. I agree to IQPC’s cancellation, substitution and payment terms Special dietary requirements: ■ Vegetarian ■ Non-dairy ■ Other (please specify) ______CANCELLATIONS AND SUBSTITUTIONS Please indicate if you have already registered by Phone ■ Fax ■ Email ■ Web ■ Delegates may be substituted at any time. IQPC does not provide refunds for cancellations. However, save where written notice of cancellation is received Please note: if you have not received an acknowledgement before the conference, please call us to confirm your booking. less than seven (7) days prior to the conference, a credit to the value paid at that date will be issued, which may be used against another IQPC conference for up to one year from its date of issue. In the event that IQPC cancels an PAYMENT METHODS event, payments received at the cancellation date will be credited towards attendance at a future IQPC conference or, in the event of a postponement by Cheque enclosed for £ ...... : (Made payable to IQPC Ltd.) IQPC, a rescheduled date. If the delegate is unable to attend the rescheduled By Direct Transfer: (Please quote EL12484B with remittance advice) event, the delegate will receive a credit in lieu of payments made towards a future IQPC event, valid for one year from the date of issue. IQPC is not IQPC Bank details: HSBC Bank, 67 George Street, Richmond, Surrey, TW9 1HG. Sort Code: responsible for any loss or damage as a result of a substitution, alteration, 40-38-18 Account No: 51304143 Swift Code: MIDLGB22 IBAN Code: GB59MIDL40381851304143 postponement or cancellation of an event due to causes beyond its control including, without limitation, natural disasters, sabotage, accident, trade or By Credit Card: Please debit my credit card: ■ ■ ■ industrial disputes or hostilities. SPEAKER CHANGES - Occasionally it is necessary for reasons beyond our Card No ■■■■■■■■■■■■■■■■ Expiry date ■■■■ control to alter the contents and timing of the programme or the identity of the speakers DATA PROTECTION - Personal data is gathered in accordance with the Data Conference No: EL12484B Conference Cardholder’s name ______Signature ______Protection Act 1998. Your details may be passed to other companies who wish to communicate with you offers related to your business activities. If you Card billing address (if different from Co. address) ______do not wish to receive these offers, please tick the box below.

______Country ______Postcode ______■ Please do not pass my information to any third party

Office use only Payment is required by return. Your place at the conference is not guaranteed until payment has been received. © IQPC Ltd. 2005 UK VAT registration no. GB 799 2259 67